


Click to verify



OpenEvidence has closed a \$210m Series B funding round at a \$3.5bn valuation, with Google Ventures and Kleiner Perkins co-leading the investment. The Cambridge-based medical AI company has raised more than \$300m since its founding and now serves over 40% of physicians in the United States who log in daily to make clinical decisions. The platform operates across more than 10,000 hospitals and medical centres nationwide, with over 65,000 new verified US clinician registrations each month. In July 2024, OpenEvidence supported approximately 358,000 logged-in physician consultations in one month. One year later, the platform now handles that volume each workday. OpenEvidence DeepConsult targets complex medical research OpenEvidence has announced the wide release of OpenEvidence DeepConsult, described as the first AI agent purpose-built for physicians. The system uses reasoning models to autonomously analyse and cross-reference hundreds of peer-reviewed medical studies in parallel, providing comprehensive research reports that would otherwise require months of human effort. Each DeepConsult run requires over 100 times the compute and cost of a standard OpenEvidence search. While some foundation model companies have publicly speculated about charging tens of thousands of dollars per month for PhD-level agents still under development, OpenEvidence offers DeepConsult free to all verified US clinicians. "At a time when US healthcare faces the dual challenges of clinician burnout and a projected physician shortfall of nearly 100,000 by 2030, the question of AI's role in bridging the gap is paramount," says Daniel Nadler, founder of OpenEvidence. "When physicians' lives are hard, patients' lives are harder." MIAMI / LONDON (IT BOLTWISE) – OpenEvidence, ein aufstrebendes Startup im Gesundheitswesen, hat sich zum Ziel gesetzt, die Art und Weise zu verändern, wie Ärzte auf medizinische Forschung zugreifen und diese nutzen. Mit einer beeindruckenden Bewertung von 3,5 Milliarden US-Dollar und einer Finanzierung von 210 Millionen US-Dollar hat das Unternehmen unter der Leitung von Daniel Nadler, einem erfahrenen Unternehmer, der bereits ein erfolgreiches Unternehmen verkauft hat, einen bedeutenden Meilenstein erreicht. Heutige Tagesdeals bei Amazon! - \$ - OpenEvidence hat sich als unverzichtbares Werkzeug für Ärzte etabliert, die mit der schieren Menge an medizinischen Veröffentlichungen zu kämpfen haben. Jeden Tag erscheinen unzählige neue Studien, und die Herausforderung, diese Informationen effizient zu verarbeiten, ist enorm. Daniel Nadler, Mitbegründer und CEO von OpenEvidence, erkannte dieses Problem und entwickelte eine KI-gestützte Lösung, die Ärzten hilft, relevante Informationen schnell und präzise zu finden. Die Technologie von OpenEvidence durchsucht Millionen von Fachpublikationen und bietet Ärzten die Möglichkeit, die besten Antworten auf klinische Fragen zu finden. Dabei werden die Informationen mit vollständigen Zitaten bereitgestellt, sodass Ärzte bei Bedarf tiefer in die Materie eintauchen können. Diese innovative Lösung ist für verifizierte Ärzte kostenlos und wird durch Werbeeinnahmen finanziert, ähnlich wie bei Google. Seit seiner Gründung im Jahr 2022 hat OpenEvidence bereits 40% der US-amerikanischen Ärzte als Nutzer gewonnen und wächst weiterhin rasant. Die Werbeeinnahmen des Unternehmens belaufen sich auf geschätzte 50 Millionen US-Dollar jährlich. Investoren wie GV und Kleiner Perkins haben großes Vertrauen in das Potenzial von OpenEvidence und unterstützen das Unternehmen finanziell. Die Herausforderung, die OpenEvidence angeht, wird durch die zunehmende Komplexität der medizinischen Forschung und den Mangel an medizinischem Fachpersonal noch verschärft. Die KI-Technologie des Unternehmens bietet eine Lösung, die Ärzten hilft, fundierte Entscheidungen zu treffen, ohne sich ausschließlich auf ihr Bauchgefühl verlassen zu müssen. Obwohl es bereits andere Unternehmen gibt, die ähnliche Lösungen anbieten, hebt sich OpenEvidence durch seine KI-Integration von Anfang an ab. Die Software wird bereits in Millionen von Konsultationen pro Monat eingesetzt und hat sich als zuverlässiges Werkzeug erwiesen, das Ärzten hilft, die bestmögliche Versorgung zu gewährleisten. Die Zukunft von OpenEvidence sieht vielversprechend aus, da das Unternehmen plant, seine Technologie weiterzuentwickeln und international zu expandieren. Mit der Einführung neuer Funktionen wie DeepConsult, die Ärzten helfen, komplexe Forschungsfragen zu beantworten, ist OpenEvidence auf dem besten Weg, eine zentrale Rolle im Gesundheitswesen zu spielen. Amazon-Kreditkarte ohne Jahresgebühr mit 2.000 Euro Verfügungsrahmen bestellen! Alle KI-Gadgets auf Amazon ansehen! Unseren KI-Morning-Newsletter «Der KI News Espresso» mit den besten KI-News des letzten Tages gratis per eMail - ohne Werbung: Hier kostenlos eintragen! OpenEvidence: KI-gestützte Lösung revolutioniert medizinische Forschung (Foto: DALL-E, IT BOLTWISE) Ergänzungen und Infos bitte an die Redaktion per eMail an de-info[at]it-boltwise.de. Da wir bei KI-erzeugten News und Inhalten selten auftretende KI-Halluzinationen nicht ausschließen können, bitten wir Sie bei Falschangaben und Fehlinformationen uns via eMail zu kontaktieren und zu informieren. Bitte vergessen Sie nicht in der eMail die Artikel-Headline zu nennen: "OpenEvidence: KI-gestützte Lösung revolutioniert medizinische Forschung". Medical knowledge doubles every 73 days. This means science is advancing faster than doctors can possibly keep up, creating a dangerous gap between breakthrough discoveries and actual patient treatment. When I first met Daniel Nadler, he told me something that stuck with me: "This isn't just a technology problem—it's a human problem." He was right, and OpenEvidence is the solution. GV just led OpenEvidence's Series B, and I'm excited to join the board and support Daniel and team. OpenEvidence is an AI-powered application that allows physicians to ask natural language questions and get immediate answers grounded in peer-reviewed medical evidence from sources like the New England Journal of Medicine and JAMA. The mission is simple but profound: organize and expand global medical knowledge so that every clinician can access the latest breakthrough discoveries at the moment of care. What Daniel has built since launching in 2023 is staggering. OpenEvidence has seen adoption by doctors faster than any technology in history aside from the iPhone. In July of last year, OpenEvidence had ~358,000 physician consultations in one month. Last week they hit that same number—in a single day. Today, it's used by more than 40% of physicians in the United States, who log in daily, on average. The patient impact is extraordinary: 1 in 3 Americans this year were treated by a physician using the platform. This explosive adoption speaks to the incredible product-market fit, but it's also a result of Daniel's unorthodox DTC (Direct to Clinician) approach. You don't pay, you just start using it. Instead of trying to sell into huge medical institutions, he's letting practitioners use it for free and building adoption from the ground up. Word of mouth is responsible for much of their growth, which has allowed them to be the most capital efficient of the breakout AI applications GV has been tracking. Daniel's history with GV goes back much further than mine—we were early investors in his first company, Kensho, in 2013. During my first meeting with Daniel, I wanted to invest immediately. But what really sealed it for me was the shared enthusiasm from our life sciences team. My colleagues in life sciences are doctors and researchers by training, and they started hearing about OpenEvidence from colleagues at medical institutions nationwide. After trying it themselves, they realized OpenEvidence was nailing answers that other platforms couldn't match. Krishna Yeshwant, a physician who co-leads our life sciences investment team, started using it daily, replacing tools he'd relied on for years. The defining moment came in Daniel's living room. Krishna and my colleagues from Cambridge arrived for what was supposed to be a 90-minute meeting. Six of us spent the entire day with Daniel, and by the end of the evening offered to invest on the spot. What drew us in wasn't just the product—it was Daniel himself. He's that rare founder who isn't motivated by the same things as most people. His fear isn't failure; it's not achieving true greatness. Daniel is building something that compounds forever, and is already starting to be accessed by healthcare professionals around the globe, and that obsession with legendary outcomes is exactly what we look for. Daniel's history with GV goes back much further than mine—we were early investors in his first company, Kensho, in 2013. That relationship and track record made this decision very much compelling. Daniel has secured partnerships with the American Medical Association, the New England Journal of Medicine, and the Mayo Clinic. He was also named to the TIME100 Health list as one of the most influential people in global health. OpenEvidence is freeing physicians from drowning in exponentially growing medical knowledge, so they can focus on what matters most: caring for patients. This is the fastest-growing healthcare application ever built, and we're just getting started. GV is grateful to partner with Daniel and the entire OpenEvidence team as they build the future of medical information access. Investors include Sequoia, Google Ventures, Kleiner Perkins, Coatue, Thrive, Conviction, ICONIQ, Greycroft, Breyer Capital, BOND, Blackstone, Mayo Clinic, and others Medical technology, AI technology is utilized by doctors for diagnosing increasing the accuracy of patient treatments. Medical research and development innovation technology to improve patient health.AI startup OpenEvidence is raising a fresh round of capital from Sequoia to scale its chatbot for doctors. The new \$75 million cash injection, which has not been previously reported, values OpenEvidence at \$1 billion, the two companies told CNBC. OpenEvidence, based in Cambridge, Massachusetts, was founded by Daniel Nadler. He previously built Kensho Technologies, a Wall Street-focused artificial intelligence firm that sold to Standard & Poor's for \$700 million in 2018. Nadler's newest AI venture is a chatbot for physicians that helps them make better decisions at the point of care. The company claims it's already being used by a quarter of doctors in the U.S. Following his sale of Kensho, Nadler self-funded OpenEvidence in 2021 before raising a friends and family round in 2023. The funding from Sequoia represents the first round led by an institutional investor and brings the company's total amount raised to more than \$100 million.The company will also use the funding to forge strategic content partnerships, OpenEvidence said. In addition to the funding, OpenEvidence announced that The New England Journal of Medicine has become a content partner, meaning clinicians using OpenEvidence can benefit from content sourced from NEJM Group journals.The founder describes OpenEvidence as an AI copilot. While the experience may feel similar to ChatGPT, OpenEvidence is a "very different organism" due to the data it was trained on, Nadler said. "Trust matters in medicine, and the fact that it's trained on The New England Journal of Medicine, the fact that it's built from the ground up for doctors -- the result is a black-and-white difference in terms of accuracy," Nadler told CNBC.The company has licensing agreements with peer-reviewed medical journals, and OpenEvidence's model was not connected to the public internet while trained, Nadler said. Using tailored data helped OpenEvidence avoid the pitfalls of "hallucination," which is a phenomenon where AI will generate inaccurate, sometimes nonsensical answers to a query.OpenEvidence offers its chatbot for free and makes money off of advertising. The product has grown organically thanks to word of mouth between doctors, Nadler said."Doctors work very close quarters with one another, especially on the floor in hospitals," he said. "When one doctor pulls out their iPhone and looks at something, other doctors can see that. Their natural question is, 'What's that?'" That level of organic growth was an alluring factor for Sequoia partner Pat Grady, who led the firm's investment. Sequoia is best known for early investments in Nvidia, Apple, YouTube, Stripe, SpaceX and Airbnb."This is a consumer internet company masquerading as a health-care business," Grady told CNBC, saying OpenEvidence is easy for doctors to adopt. "When they have a couple of good experiences with it, it sticks. There aren't a lot of products in health care that get adopted the way that a consumer internet company might."OpenEvidence is the latest in a flood of Silicon Valley artificial intelligence deals. The booming sector accounted for 1 in 4 venture dollars raised by startups last year, according to CB Insights. Health care has stood out as a high-potential area for the application of AI. Investors and founders have seen the technology's ability to sift through large amounts of data, and its potential to transform everything from drug discovery to medical imaging."There are a lot of great ideas in health care, but it is such a complex system," Grady said. "It's really hard to cut through layer upon layer upon layer." While AI has the potential for health-care breakthroughs, there are also worries about the risks. Industry leaders have voiced concern about a "doomsday" scenario where the technology leads to a catastrophic outcome for humanity, and on the smaller scale, others worry about job displacement.OpenEvidence's Nadler said he thinks the health-care use cases are the antidote, and represent the upside potential of AI. He highlighted doctor burnout and projections of an almost 100,000 physician shortfall by the end of the decade. "There's this big question that's on everybody's mind right now, is AI actually going to be good for humanity or not?" Nadler said. "I think it is, inarguably, going to be good." 7. August 2025 OpenEvidence, ein auf Künstliche Intelligenz spezialisiertes Unternehmen für medizinische Fachanwendungen, hat in einer neuen Finanzierungsrunde 210 Mio. US-\$ erhalten. Die Bewertung liegt damit bei 3,5 Mrd. US-\$, ein Anstieg gegenüber 1 Mrd. US-\$ im Februar 2025. Das Unternehmen wurde 2022 von Daniel Nadler und Zack Ziegler gegründet. Ziel von OpenEvidence ist die automatisierte Auswertung medizinischer Fachliteratur. Die KI-Plattform durchsucht Millionen von peer-reviewed Studien, darunter Veröffentlichungen aus Fachzeitschriften wie dem New England Journal of Medicine oder der Journal of the American Medical Association (JAMA). Die Software liefert präzise Suchergebnisse mit Quellenangabe. Sie ist kostenlos für approbierte Ärzt:innen zugänglich und finanziert sich über Werbung. Aktuell nutzen rund 430.000 registrierte Mediziner:innen in den USA das System – rund 40 % aller praktizierenden Ärzt:innen im Land. Monatlich kommen etwa 65.000 neue Nutzer:innen hinzu. Die Anwendung wird derzeit in rund 8,5 Mio. Konsultationen pro Monat eingesetzt. Der geschätzte annualisierte Werbeumsatz liegt laut Unternehmensangaben bei 50 Mio. US-\$. OpenEvidence wurde von Nadler mit rund 10 Mio. US-\$ Eigenkapital finanziert. Er hält rund 60 % der Unternehmensanteile. Forbes schätzt sein Vermögen auf 2,3 Mrd. US-\$. CTO Zack Ziegler besitzt ca. 10 %, entsprechend einem Anteil im Wert von 350 Mio. US-\$. Zu den Investor:innen zählen GV (Google Ventures), Kleiner Perkins, Coatue, Conviction und Thrive Capital. John Doerr, Chairman von Kleiner Perkins, bezeichnete das Modell als potenziellen Standard in der medizinischen Informationssuche. Die zugrunde liegende Marktlogik ist die steigende Unübersichtlichkeit medizinischer Forschung: Pro Jahr erscheinen Millionen neuer Studien. Viele sind veraltet, widersprüchlich oder nicht klinisch relevant. Gleichzeitig nimmt der Zeitdruck für Ärzt:innen mit zunehmenden Patientenzahlen und Fachkräftemangel zu. KI-gestützte Tools zur Literatursauwertung gelten daher als Wachstumskategorie im Healthtech-Sektor. OpenEvidence unterscheidet sich von bestehenden Angeboten wie UpToDate durch die vollständige KI-Integration seit Gründung. Die Software ist nicht als diagnostisches Werkzeug klassifiziert und unterliegt daher nicht der FDA-Zulassungspflicht. Eine separate Vertriebschiene über Krankenhäuser entfällt, da die Nutzung direkt über Browser oder App erfolgt. Ein neues Modul namens DeepConsult soll ärztliche Entscheidungsprozesse durch sogenannte „Reasoning Models“ unterstützen – also durch KI-Modelle, die medizinische Zusammenhänge schrittweise analysieren. Ziel ist eine präzisere Einordnung von Studienergebnissen bei komplexen Fragestellungen. Eine internationale Expansion wird vorbereitet, zunächst fokussiert sich das Unternehmen jedoch weiter auf den US-Markt. Das Unternehmen ist Teil des Mayo Clinic Accelerator Programms und arbeitet eng mit medizinischen Einrichtungen zusammen. Laut Angaben von Coatue-Mitgründer Thomas Laffont könnte OpenEvidence künftig zu einer Plattform werden, die weitere klinische Tools integriert – etwa Patientendaten, Laborwerte und externe Geräte wie Blutzuckermesssysteme. Text: Amy FeldmanFoto: imdb Medical information platform OpenEvidenceCompany typePrivateIndustryArtificial intelligenceFounded2022FoundersDaniel Nadler, Zachary ZieglerHeadquartersMiami, Florida, United StatesKey peopleDaniel Nadler (Co-founder & CEO) Zachary Ziegler (Co-founder)Websitewww.openevidence.com OpenEvidence is an American artificial intelligence company that develops a medical search engine used by physicians for clinical decision support. The company was founded in 2022 by entrepreneur Daniel Nadler and is headquartered in Miami, Florida.[1] OpenEvidence was founded in 2022 by Daniel Nadler, a Harvard Ph.D. and former founder of Kensho, a financial analytics firm acquired by S&P Global in 2018.[2][3] Nadler launched the company with co-founder Zack Ziegler, a machine learning researcher from Harvard, to address the challenge physicians face in keeping up with the growing volume of medical literature.[1][4] In 2023, OpenEvidence reported that its artificial intelligence model achieved a 90 percent score on the United States Medical Licensing Examination (USMLE).[5] During the same year, the company participated in the Mayo Clinic health-technology accelerator.[6] In 2025, the company stated that the model had reached a 100 percent score on the same examination.[4][7] In February 2025, OpenEvidence raised \$75 million in a Series A round led by Sequoia Capital, valuing the company at \$1 billion.[8] In July 2025, the company secured \$210 million in funding from a round led by GV (Google Ventures) and Kleiner Perkins, with participation from Coatue, Conviction, and Thrive Capital. This round valued the company at \$3.5 billion.[9] OpenEvidence has also announced partnerships with organizations including the American Medical Association, The New England Journal of Medicine, and several specialty journals published by the JAMA Network.[4][10][11] On 20 October 2025, the company announced a US\$200 million Series C funding round, valuing the company at US\$6 billion.[12] OpenEvidence provides an artificial intelligence-based platform that analyzes and organizes peer-reviewed medical literature from clinical journals such as The New England Journal of Medicine and The Journal of the American Medical Association. According to the company, access is available at no cost to verified physicians, with revenue derived from advertising. As of July 2025, the company reported more than 430,000 registered U.S. physicians (about 40% of U.S. physicians) and use in over 8.5 million consultations per month. In the same month, OpenEvidence introduced a feature called DeepConsult, described as employing reasoning models to synthesize findings across multiple studies.[6] In 2025, Daniel Nadler, co-founder of OpenEvidence, was named to the TIME100 Health list of the 100 most influential people in global health.[13] Clinical decision support system Generative artificial intelligence ^ a b Feldman, Amy. "OpenEvidence Cofounder Daniel Nadler Is Now A Billionaire". Forbes. Retrieved 2025-10-03. ^ Bertoni, Steven. "Can Kensho Bring Google Style Search To Stock Picking?". Forbes. Retrieved 2025-10-03. ^ Gara, Antoine. "Wall Street Tech Spree: With Kensho Acquisition S&P Global Makes Largest A.I. Deal In History". Forbes. Retrieved 2025-10-03. ^ a b c Landi, Heather (2025-08-15). "OpenEvidence AI scores 100% on USMLE, launches explanation model". www.fiercehealthcare.com. Retrieved 2025-10-01. ^ Roger, Olivia (July 14, 2023). "OpenEvidence's gen AI beats ChatGPT, Med-PaLM 2 on US medical licensing exam". firstwordhealthtech.com. Retrieved 2025-10-03. ^ a b Feldman, Amy. "How OpenEvidence Cofounder Daniel Nadler Became A Billionaire". Forbes ME. Retrieved 2025-10-03. ^ "Medical AI Firm Says Competitor Hacked Prompts to Steal Secrets". 2025-06-23. Archived from the original on 2025-07-24. Retrieved 2025-10-03. ^ Rooney, Kate (2025-02-19). "AI health-care startup OpenEvidence raises funding from Sequoia at \$1 billion valuation". CNBC. Retrieved 2025-10-03. ^ Balasubramanian, Sai. "OpenEvidence's Meteoric Rise Is Huge For Doctors". Forbes. Retrieved 2025-10-03. ^ Haupt, Angela. "TIME100 Health: Daniel Nadler". TIME. Archived from the original on 2025-06-16. Retrieved 2025-10-03. ^ "How What is OpenEvidence? AI Medical Search for Physicians". aiforsocialgood.ca. 2025-10-15. Retrieved 2025-10-15. ^ "OpenEvidence Raises \$200 Million for a ChatGPT for Medicine". 2025-10-20. Retrieved 2025-11-11. ^ Law, Marcus (2025-07-17). "How OpenEvidence AI is Transforming Clinical Decision-Making". aimagazine.com. Retrieved 2025-10-01. Official website Retrieved from " OpenEvidence 2.0 Now AvailableOpenEvidence Adds Administrative and Clinical Workflows, Calculators, and Enhanced Primary Evidence ModulesWe are excited to announce OpenEvidence 2.0. In addition to medical search, OpenEvidence now fully supports administrative and clinical workflow use cases, including:Administrative tasks like writing prior authorization letters (based on the evidence, including citations and references)Drafting patient handoutsUpgraded diagnostic reasoning supportSupport for 50+ widely used clinical calculatorsDetailed drug monograph modules and delineated guideline-based modulesSupport for tables on demandA wider accepted scope of questions to support the expansion of use cases.OpenEvidence remains free for verified U.S. doctors, and the above features are already automatically enabled. All you need to do is use OpenEvidence as you normally would, but expand the types of questions you ask. Try asking questions like this to explore the new capabilities in OpenEvidence 2.0:Write a prior auth letter requesting coverage for "Calculate the CHA2DS2-VASC score for "Write home care instructions for a patient who "We are dedicated to providing high-quality, evidence-based information at your fingertips. In this update, OpenEvidence maintains its emphasis on grounding information in verifiable, trustworthy sources and builds on that foundation to support a wide range of physician needs.If you have feedback or suggestions, please contact us and share your thoughts.– See all announcements

- http://mayphotocopydogia.com/upload/files/jixugap.pdf
- vovuu
- vaylju
- http://thefirm.com/userfiles/file/nalatidexafil.pdf
- http://rund.cz/UserFiles/File/92985901090.pdf
- http://savaksangida.com/resimler/files/68682883821.pdf